EUVIMEDEUVIMED entdecken
Crossref

Cabazitaxel prodrug nanoassemblies with branched chain modifications: Narrowing the gap between efficacy and safety

Hezhen Xu, Shiyi Zuo, Danping Wang, Yu Zhang, Wenxiao Li, Lingxiao Li, Tian Liu, Yuanhao Yu, Qingzhi Lv, Zhonggui He, Jin Sun, Bingjun Sun

Journal of Controlled Release · 2023

DOI: 10.1016/j.jconrel.2023.07.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Hezhen Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Prodrugs, Nanoparticles. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical application of cabazitaxel (CTX) is restricted by severe dose-related toxicity, failing to considering therapeutic efficacy and safety together. Self-assembled prodrugs promote new drug delivery paradigms as they can self-deliver and self-formulate. However, the current studies mainly focused on the use of straight chains to construct self-assembled prodrugs, and the role of branched chains in prodrug nanoassemblies remains to be clarified. In this study, we systematically explored the structure-function relationship of prodrug nanoassemblies using four CTX prodrugs that contained branched chain aliphatic alcohols (BAs) with different alkyl lengths. Overall, CTX-SS-BA20 NPs with the proper alkyl length exhibited significant improvements in both antitumor efficacy and biosafety. Furthermore, compared with straight chain (SC) modified prodrug nanoassemblies (CTX-SS-SC20 NPs), CTX-SS-BA20 NPs still hold great therapeutic promise due to its good biosafety. These findings illustrated the significance of BAs as modified chains in designing prodrug nanoassemblies for narrowing the efficacy-to-safety gap of cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNanoparticlesDrug Delivery SystemsTaxoidsCell Line, Tumor

Stichwörter der Autor:innen

Branched chain aliphatic alcoholsCabazitaxelDisulfide bondProdrug nanoassembliesToxicity-reducing and efficacy-enhancing

Substanzen

ProdrugscabazitaxelTaxoids

Autor:innen und Institutionen

  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • School of Pharmacy, Binzhou Medical University, Binzhou 256603, China.
  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: sunjin@syphu.edu.cn.
  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: sunbingjun_spy@sina.com.

Zitieren

APA

Xu, H., Zuo, S., Wang, D., Zhang, Y., Li, W., Li, L., Liu, T., Yu, Y., Lv, Q., He, Z., Sun, J., & Sun, B. (2023). Cabazitaxel prodrug nanoassemblies with branched chain modifications: Narrowing the gap between efficacy and safety. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.07.012

Vancouver

Xu H, Zuo S, Wang D, Zhang Y, Li W, Li L, et al. Cabazitaxel prodrug nanoassemblies with branched chain modifications: Narrowing the gap between efficacy and safety. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.07.012

BibTeX
@article{Xu2023,
  author = {Xu, Hezhen and Zuo, Shiyi and Wang, Danping and Zhang, Yu and Li, Wenxiao and Li, Lingxiao and Liu, Tian and Yu, Yuanhao and Lv, Qingzhi and He, Zhonggui and Sun, Jin and Sun, Bingjun},
  title = {Cabazitaxel prodrug nanoassemblies with branched chain modifications: Narrowing the gap between efficacy and safety},
  journal = {Journal of Controlled Release},
  year = {2023},
  doi = {10.1016/j.jconrel.2023.07.012}
}
Kostenlos starten →